




RealRate

PHARMACEUTICAL 2014

Biomarin Pharmaceutical INC
Rank 96 of 234

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 285%, being 42% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	1,137,418
Cost of Goods Sold	95,742
Intangible Assets	217,405
Liabilities, Current	183,271
Liabilities, Non-Current	38,549
Other Assets	575,078
Other Compr. Net Income	5,220
Other Expenses	41,876
Other Liabilities	686,356
Other Net Income	2,916
Other Revenues	548,485
Property and Equipment	319,316
Research and Development	354,780
Selling, General and Administrative Expense	235,356

Output Variable	Value in 1000 USD
Assets	2,249,217
Liabilities	908,176
Expenses	727,754
Revenues	548,485
Stockholders Equity	1,341,041
Net Income	-176,353
Comprehensive Net Income	-173,743
BaseVar	2,220,884
ECR before LimitedLiability	174%
Economic Capital Ratio	285%